Gian Manuel Jmz Rdz

Cardiólogo.
PO-ICU
#congenitalheart
#interventionalcardilogy 🇲🇽
#structuralheart UMC Utrecht 🇳🇱
#cardiotwitter #radialfirst

[European Society of Cardiology Journals @ESC_Journals]

❤️ When should Lp(a) be measured after AMI? The FRENCHIE-Lp(a) study shows that 1 in 3 patients changed Lp(a) risk category over time #EJPC #Lp(a) ⤵️ https://t.co/scl6LtKJoq

@escardio @AboyansV @SilCastelletti @PeroneFrancesco @PTBuketAkinci @SMosteoru @TimKambic

[European Society of Cardiology Journals @ESC_Journals]

✅Lp(a) at the #AHA26 - no 💊 pharma yet on the HORIZON. So should we still screen it ? Does Knowing Lp(a) Change What We Do? See the debate in #EJPC ⤵️ https://t.co/JhzEq60CVo

@escardio @AboyansV @SilCastelletti @PeroneFrancesco @PTBuketAkinci @SMosteoru @TimKambic @GalTsaban @DLBHATTMD

[NEJM @NEJM]

Presented at #ScientificSessions26:

In patients with atrioventricular block, left bundle-branch pacing resulted in a lower incidence of a composite of death, hospitalization for heart failure, or pacing-induced cardiomyopathy than right ventricular pacing. Full OptimPacing trial results: https://t.co/Fg0lv9xcka

@AHAScience

[Michael Megaly @MichaelMegalyMD]

Great tool for fellows to learn peripheral anatomy!

[Salman Arain @realarainmd]

If Not Periprocedural Myocardial Injury, Or Vascular Complications, Then What?

The latest CHIP-BCIS3 analysis adds another twist to the tale. While mAFP use was associated with higher rates of PPMI and CV death, the former only partially explained the latter.

This is perplexing. That mAFP failed to outperform standard-of-care HR-PCI is understandable, but the association with higher mortality is unexpected, and at odds with our clinical experience.

The fig. below, from the supplement, shows that the curves diverge on Day 1. Whatever the mechanism, it must be procedure-related.

My best guess? Myocardial stunning, reflected by loss of pulse pressure (LOPP). Perhaps the real story here is that:
1) Stunning can occur without myocardial necrosis.
2) LOPP may impose an independent, additive burden on patients undergoing HR-PCI.

An intriguing possibility! 🤔

[Srihari S. Naidu, MD @SrihariNaiduMD]

Nicely packaged here. Appreciate your deep dive!

[Alex Truesdell @agtruesdell]

1/3 @SCAI SHOCK⚡️🫀💥 Update 2026 Part 1 👉: 🔗 https://t.co/fP3PuAXYap…

[Carlos Collet MD PhD @ColletCarlos]

Coronary CT #CCTA takes center stage at #TCT2026!

A mobile CT scanner right in the Expo Hall, where attendees are undergoing coronary CT scans with real-time analysis using @HeartFlow technology.

Bringing the future of CT-guided PCI directly to TCT!

[Gian Manuel Jmz Rdz @drgianma]

A new score to predict the need of mechanical support before PCI.
Oracle

https://t.co/lsoX0wxxUR

#TCT2026
@TCTConference

[JACC Journals @JACCJournals]

#TCT2026: PARADIGM met its primary endpoint, with favorable short-term outcomes. The results support this transcatheter device as a promising therapeutic option for paravalvular leak closure. 🔗 https://t.co/eaTuc799Jb

#JACCINT @crfheart

[Angel Caldera @caldera_99]

🚨 PROGRESS results are out! TAVR is superior to clinical surveillance in selected patients with MODERATE aortic stenosis and at-risk features. A potential shift toward earlier intervention—with careful patient selection. #TCT2026 #TAVR @crfheart Great presentation from @PhilGenereuxMD 👏👏👏

https://t.co/qK58S0tZY4

[Gian Manuel Jmz Rdz @drgianma]

CT-guided PCI.

Is it going to be the future standard of care?

I think so.

#TCT2026 #PCI @ColletCarlos

[Cardiovascular Research Foundation @crfheart]

🌴 Day 1 was one to remember. And we’re just getting started!

Thank you to everyone who made yesterday so special. We’re kicking off Day 2 of #TCT2026 with even more science, innovation, and unforgettable moments ahead.

✨ Here’s to another incredible day!

#CardioX #CardioTwitter #CardioEd #CardioResearch @BurkhoffMd @djc795 @ColletCarlos @georgedangas @jgranadacrf @mbmcentegart @Drroxmehran @sahilparikhmd @PopmaJeffrey @triciarawh @mirvatalasnag @TCTConference @TCTMD @m1chaella_alex @CathWhisperer @caldera_99 @SinaDaneshMD @CAESmedmd @Julio_Farjat @GolzarianH @JyotiJain_MD @Shikha_Cardio @DrBilal_khan @KrutarthKPandya @Shoaib9702 @IoannisSkalidis @Sticchi_Alex @ricosuruagy @ladyheart_md @AnaClaraVi75147 @anast_apost @padideh_daneii @MAnisHaider @Rushil_Vasudev

[Gian Manuel Jmz Rdz @drgianma]

Arriving to San Diego for #TCT2026.

See you in #complexPCI #TAVR and #SHOCK sessions.

[EuroIntervention @EuroInterventio]

In STEMI patients with multivessel disease, reduced LVEF increases ischaemic risk — but the COMPLETE trial showed complete revascularisation reduces major CV events regardless of LVEF.

Read the full analysis by @DeniseTiong, et al.
https://t.co/QXnFk0g0C4

@ShamirMehta, @Drroxmehran, @SVRaoMD

#CardioTwitter #InterventionalCardiology #PCI #MultivesselDisease #ClinicalResearch #EvidenceBasedMedicine

[Aliyor GANIEV, MD @drAliyor]

Fundamental concept of deformability of #calcifiednodules

doi: 10.4244/EIJ-D-25-00296
#Cardiology #interventionalcardiology #coronarycalcium @ziadalinyc @realarainmd @sbrugaletta @ShariqShamimMD @evandrofilhobr @mirvatalasnag @mmamas1973 @gbiondizoccai @FaustoHerediaDr @KAlaswadMD

[European Society of Cardiology Journals @ESC_Journals]

🫀Finerenone vs spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. see@ https://t.co/syoivz0TBE

@EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava
#ESCHeartFailure

[Pablo Corral MD @drpablocorral]

👉PCSK9 gene editing: One shot. Lifelong LDL-C lowering?

☝️ A new review explores the promise and challenges of CRISPR-based PCSK9 gene editing.

1️⃣ One-time treatment: A single infusion could provide lifelong reductions in PCSK9 expression and LDL-C.

2️⃣ Early human evidence: VERVE-102 and YOLT-101 have demonstrated substantial LDL-C reductions, reaching approximately 50% at selected doses.

3️⃣ The major advantage: Decades of LDL-C lowering without repeated dosing. A potentially transformative approach to cumulative cholesterol exposure.

4️⃣ Safety considerations: Early clinical results are encouraging. Larger studies and longer follow-up are needed to establish long-term safety and durability.

☝️ The next frontier: Can sustained LDL-C reduction from a single intervention translate into greater lifetime cardiovascular protection?

🔗🔓 https://t.co/x1njFU9mwy

@amitvkhera
@society_eas

[Jonathan X Fang, MBBS, FACC, FSCAI @fangjonathanx]

AngioVAC for left-sided intracardiac masses shows good effectiveness. Careful case selection, timely workup, and optimal embolic protection strategy are necessary. @PedroMDMSc @ShimamuraMD @DrMarvinEng @AhmadJabri8 @g_giustinoMD @vonBardelebenRS @engelpedro @Tiberio_Frisoli

[Journal of Cardiovascular CT @journalCCT]

Tomizawa et al. found that super-resolution deep learning reconstruction (SR-DLR) improved CT-FFR performance, increasing AUC from 0.72 to 0.85 and diagnostic accuracy from 74% to 85% vs. normal-resolution DLR (NR-DLR).

https://t.co/RciCreV6sk